Table 1.
Baseline characteristics.
| All patients (n = 121) | ABMR/MVI (n = 46) | Control group (n = 75) | p-Value | |
|---|---|---|---|---|
| Recipient demographics | ||||
| Sex (female), n (%) Age (years), mean ± SD Ethnicity (Caucasian), n (%) Body mass index (kg/m2), mean ± SD Type 2 diabetes, n (%) Cause of end-stage renal, n (%) - Immune-mediated disease - Cystic kidney disease - Diabetic nephropathy - Vascular disease - Tubulointerstitial disease - Unknown - Other disease KT preemptive, n (%) Median time on dialysis (months, IQR) |
54 (44.6) 54.5 ± 13.2 99 (81.8) 27.0 ± 5.7 36 (29.8) 22 (18.2) 15 (12.4) 19 (15.7) 15 (12.4) 11 (9.1) 29 (24) 10 (8.3) 15 (12.4) 20 (9–34.5) |
28 (60.9) 53.7 ± 14.6 39 (84.8) 27.1 ± 6.3 13 (28.3) 8 (17.4) 7 (15.2) 7 (15.2) 5 (10.9) 2 (4.3) 13 (28.3) 4 (8.6) 7 (15.2) 16 (11–41) |
26 (34.7) 54.9 ± 12.3 60 (80.0) 27.0 ± 5.3 23 (30.7) 14 (16.5) 10 (11.8) 13 (15.2) 11 (12.9) 10 (11.8) 21 (24.7) 6 (7.1) 8 (10.7) 20.5 (9–33.8) |
0.005 0.637 0.508 0.875 0.779 0.440 0.461 0.775 |
| Donor demographics | ||||
| Sex (female), n (%) Age (years), mean ± SD Donor type, n (%) - Living donor - Donation after brain death - Donation after cardiac death Median cold ischemia time (hours, IQR) Delayed graft function, n (%) |
58 (48.7) 55.7 ± 14.4 26 (21.5) 70 (57.9) 25 (20.7) 12 (5–16.5) 31 (25.6) |
20 (45.5) 54.8 ± 15.4 10 (21.7) 28 (60.9) 8 (17.4) 13 (7–16) 15 (32.6) |
38 (50.7) 56.3 ± 13.7 16 (21.3) 42 (56) 17 (22.7) 10.5 (4.6–17) 16 (21.3) |
0.583 0.569 0.778 0.530 0.168 |
| Transplant characteristics | ||||
| HLA cPRA over 50% before KT HLA-DSA before KT, n (%) - HLA-DSA class II Previous transplantation, n (%) Previous pregnancies, n (%) (n = 59) Blood transfusion before KT, n (%) Induction therapy (thymoglobulin), n (%) Immunosuppression regimen (tacrolimus, mycophenolate, and steroids), n (%) |
20 (16.5) 11 (9.1) 8 (72.7) 11 (9.1) 44 (81.5) 47 (38.8) 18 (15) 95 (78.5) |
13 (28.3) 9 (19.6) 6 (66.7) 7 (15.2) 23 (82.1) 20 (43.5) 11 (24.4) 35 (76.1) |
7 (9.3) 2 (2.7) 2 (100) 4 (5.3) 21 (80.8) 27 (36) 7 (9.3) 60 (80) |
0.007 0.002 0.066 0.897 0.413 0.025 0.611 |
| Follow up | ||||
| Median time of follow-up (months, IQR) Graft loss death censored at end of follow-up, n (%) |
79 (58–98) 15 (12.4) |
77 (51–106) 12 (26.1) |
81.5 (64–95) 3 (4) |
0.309 <0.001 |
| Graft function at biopsy | ||||
| Median time from KT to biopsy (months, IQR) Renal function: - Serum creatinine (mg/dl) mean ± SD - eGFR (MDRD) (ml/min) mean ± SD - Urine protein/creatinine ratio (mg/g) mean ± SD HLA-DSA, n (%) |
13 (12–16) 1.6 ± 0.7 49.3 ± 20.3 336 ± 462.4 26 (21.5) |
14 (12–37.3) 1.8 ± 0.9 44.7 ± 17.4 428.9 ± 483.2 23 (50) |
13 (12–15) 1.5 ± 0.6 52 ± 21.6 283.2 ± 450 3 (4) |
0.016 0.050 0.070 0.084 <0.001 |